

Vermont Vaccine Purchasing Program Assessment Calculation Worksheet

Column →	A	B	C	D	E
Line ↓	July 2019-June 2020		July 2019-June 2020		Comments
A. Preliminary Vaccine Cost Estimates					
01.	14,459,368		4,006,697		Estimated costs of vaccines (sheets e & f)
02.	72,297	0.50%	20,033	0.50%	Provision for vaccine utilization increase
03.	0	3.50%	140,936	3.50%	¹ Provision for vaccine cost increase (% is annual)
04.	14,531,665		4,167,666		Est. vaccines costs(w/ utilization & price adjustments.)
05.	-7,952,652		-338,378		Estimated VFC Award & 317 federal grant
06.	0		0		Other
07.	6,579,012		3,829,288		Estimated VVPP vaccine costs
08.	243,423	3.70%	141,684	3.70%	VDH operational cost
09.	6,822,435		3,970,972		Total vaccine and VDH operational costs
B. Assessable Covered Lives Estimates					
10.	59,649		342,647		Assessable covered lives (sheet c)
11.	0	0.00%	0	0.00%	Leakage (unknown insurer, out of reach entity, etc.)
12.	59,649		342,647		Assessable lives actually paying
C. Financial Carry Forwards					
13.	3,685,005		1,757,395		Vaccine fund carryforward (sheet d.)
14.	0	0.0	0	0.0	Amt. retained for liquidity reserve /reserve months
15.	3,685,005		1,757,395		Carryforward used to reduce current assessment
D. Operational and Other Fixed Costs					
16.	108,173		76,321		Administrative fees - KidsVax (from sheet b.)
17.	682	0.01%	397	0.01%	Bad debt allowance
18.	108,855		76,718		Sub-total anticipated operating costs
19.	0	0.00%	0	0.00%	Working capital reserve build-up
20.	0	0.00%	0	0.00%	Risk reserves
21.	\$ 108,855		\$ 76,718		Total fixed costs
E. Assessment Calculation					
22.	\$6,931,290		\$4,047,690		Total assessment funds needed (Row 9+ Row 21)
23.	-\$3,685,005		-\$1,757,395		Plus carry forward credit
24.	\$3,246,285		\$2,290,295		Net assessment funds needed
F. Per Assessable Covered Life Assessment					
25.	\$54.48		\$6.72		Annual assessment per covered life
26.	\$4.54		\$0.56		Monthly assessment per covered life calculated
27.	\$4.54		\$0.56		Monthly assessment per covered life recommended
G. Unexpended Assessments					
28.	682		397		² Unexpended assessments
H. Various Performance Metrics					
29.	1.64%		1.99%		Administrative fees - KidsVax as % of vaccine costs
30.	5.34%		5.69%		VDH operational cost & KV admin. fee as a % of vaccines
31.	\$9.68		\$0.98		³ "Normalized" assessment rate (w/o lines 13, & 19)
32.	113.3%		75.8%		% Change from monthly assessment rate
33.	\$10.07		\$1.02		⁴ Preliminary Assessment projection
I. Vaccine Cost per Covered Life determination					
34.	\$ 9.19		\$ 0.93		Vaccine cost calculated

Notes:

- ¹ The CDC contract prices change dates are 4/1 for childhood vaccines and 7/1 for adult vaccines. The child price increase is 0 on Line 3 because VDH anticipates purchasing vaccines administered in April-June 2020 in March 2020, at April 2019 prices. All childhood vaccine cost projections are based on April 2019 CDC pricing. The line 3 provision for cost increases is applied for 12 months for adult vaccines in order to estimate July 2019 CDC prices.
- ² Carryforward cash amounts, if any, will be used for a working capital reserve if needed, and then applied to reduce future assessments unless otherwise directed by VDH.
- ³ This rate assumes that the working capital reserve is adequate and so included no reserves and also no carry forward.
- ⁴ Preliminary projection: This is the normalized assessment rate and one additional year of inflation and utilization changes.

VT DOH Pediatric Vaccine Purchase Estimates
Federal Fiscal Year

Column →
Line ↓

	A	B	C	D	E	F	G
	Vaccine	Brand Name	VVPP Cost Per Dose ¹	Total Estimated Doses	Total Estimated Cost	FFY19 total estimated doses	FFY19 actual doses distributed 10/1/18-3/31/2019
01.	DTaP	Daptacel	\$18.07	1,160	\$20,962	960	270
02.		Infanrix	\$18.67	6,330	\$118,181	6,550	2,520
03.	DTaP-HepB-IPV	Pediarix	\$59.05	11,150	\$658,408	13,340	5,400
04.	DTaP-IPV/Hib	Pentacel	\$59.42	8,000	\$475,376	6,520	3,910
05.	DTaP-IPV	Kinrix	\$41.31	4,200	\$173,502	5,310	1,990
06.		Quadracel	\$40.67	2,000	\$81,334	1,640	910
07.	Hib	ActHIB	\$9.48	17,000	\$161,228	19,375	7,960
08.		PedvaxHIB	\$13.21	0	\$0	0	0
09.		Hiberix	\$9.46	0	\$0	0	0
10.	HepA	Vaqta	\$19.66	0	\$0	0	0
11.		Havrix	\$20.52	19,500	\$400,140	21,000	8,040
12.	HepB	Recombivax	\$12.30	5,000	\$61,500	0	2,530
13.		Engerix B	\$16.02	4,000	\$64,080	9,140	1,190
14.	HPV	Gardasil	\$178.14	18,000	\$3,206,520	18,850	7,390
15.	IPV	IPOLE	\$13.55	2,000	\$27,100	2,000	1,020
16.	Influenza	Fluzone – Quad	\$13.76	21,750	\$299,215	33,500	35,880
17.			\$13.76	21,750	\$299,215	13,000	13,500
18.		FluMist	\$18.88	7,000	\$132,160	n/a	n/a
19.		Fluarix	\$13.50	7,250	\$97,875	n/a	n/a
20.		FluLaval	\$13.50	7,250	\$97,875	14,000	14,000
21.	MMR	MMR II	\$21.22	8,000	\$169,760	8,300	2,930
22.	MMRV	ProQuad	\$131.40	7,200	\$946,080	7,400	3,130
23.	MCV4 / MenACWY	Menactra	\$93.45	11,500	\$1,074,675	11,390	5,230
24.		Menveo	\$94.84	30	\$2,845	240	5
25.	MENB	Trumenba	\$108.95	0	\$0	0	0
26.		Bexsero	\$135.48	2,500	\$338,700	2,125	655
27.	PCV13	Prevnar 13	\$137.01	25,000	\$3,425,250	25,000	11,720
28.	PPSV23	Pneumovax 23	\$56.30	200	\$11,260	230	51
29.	RV	RotaTeq	\$70.49	7,000	\$493,430	230	2,950
30.		Rotarix	\$94.69	6,000	\$568,140	12,000	2,910
31.	Td	TDVAX	\$16.03	900	\$14,424	745	400
32.	Tdap	Boostrix	\$32.24	7,200	\$232,128	4,200	3,400
33.		Adacel	\$31.75	2,500	\$79,375	5,000	1,190
34.	VAR	Varivax	\$104.09	7,000	\$728,630	8,000	2,920
35.				248,370	\$14,459,368		144,001

¹ CDC pediatric vaccine contract prices as of 4/1/19

18-19 flu season distribution 9/1/18-3/31/19

estimated VFC 55% \$7,952,652

VT DOH Adult Vaccine Purchase Estimates
Federal Fiscal Year

Column →
Line ↓

	A	B	C	D	E	F	G
	Vaccine	Brand Name	VVPP cost per dose ¹	Total Estimated Doses	Total Estimated Cost	FFY19 estimated total doses	YTD actual doses distributed 10/1/18-3/31/2019
01.	HepA	Vaqta	\$28.28	0	\$0	0	0
02.		Havrix	\$28.28	5,000	\$141,400	4,700	1,560
03.	HepB	Engerix B	\$30.81	4,000	\$123,240	4,810	1,310
04.	HepB	Heplisav-B	\$69.75	1,500	\$104,625	n/a	100
05.	HepA-HepB	Twinrix	\$56.76	2,000	\$113,520	1,600	750
06.	HPV	Gardasil	\$144.18	4,100	\$591,118	2,520	1,290
07.	Influenza	Fluarix	\$12.22	25,000	\$305,500	400	170
08.		FluLaval	\$12.22	25,000	\$305,500	n/a	n/a
09.	MMR	MMR II	\$45.65	500	\$22,825	505	110
10.	MCV4 /	Menactra	\$75.07	1,000	\$75,066	600	375
11.	MenACWY	Menveo	\$65.91	0	\$0	35	0
12.	MENB	Trumenba	\$75.81	0	\$0	0	0
13.		Bexsero	\$103.94	500	\$51,969	250	142
14.	PCV13	Prevnar 13	\$118.05	960	\$113,327	890	440
15.	PPSV23	Pneumovax 23	\$56.14	5,000	\$280,685	5,775	2,378
16.	RZV	Shingrix	\$102.19	12,000	\$1,226,280	14,500	4,060
17.	Td	TDVAX	\$13.96	7,000	\$97,748	6,620	3,472
18.	Tdap	Boostrix	\$24.65	14,000	\$345,072	14,000	4,860
19.		Adacel	\$24.49	4,000	\$97,964	3,000	1,750
20.	VAR	Varivax	\$77.57	140	\$10,859	50	60
21.				111,700	\$4,006,697		22,827

¹ CDC adult vaccine contract purchase prices as of 4/1/19

18-19 flu season distribution 9/1/18-3/31/19

estimated 317 \$338,378

Prior Year's Financial Recap

Column →	A	B	C
Line ↓			
Revenues			
01.	Carryforward from prior year (cash on hand at 10/1/17)	\$4,886,018	
02.	VVPP assessment collections over reconciliation period (10/1/17-3/31/19)	\$8,429,870	
03.	Estimated VVPP assessment collections 4/1/19-6/30/19	\$13,928	
04.	True-up Tricare settlement estimate	-\$785,867	
05.	Total Revenues		\$12,543,949
Expenditures / Allowances			
06.	Total vaccine purchases 10/1/17-3/31/19	\$6,389,569	
07.	Estimated vaccine purchase 4/1/19-6/30/19	\$187,241	
08.	KidsVax 10/1/17-3/31/19	\$302,341	
09.	Estimated KidsVax 4/1/19-6/30/19	\$24,900	
10.	VDH operational cost 10/1/17-3/31/19	\$171,248	
11.	Estimated VDH operational cost 4/1/19-6/30/19	\$26,251	
12.	Total Expenditures/Allowances		<u>-\$7,101,550</u>
13.	Vaccine Fund Carryforward ¹ (applied to reduce this year's assessment)		\$5,442,400

Notes:

¹ Excess of revenues (including prior carryforward) over expenditures.